scholarly journals Jactatio capitis nocturna with persistence in adulthood: case report

1998 ◽  
Vol 56 (3B) ◽  
pp. 655-657 ◽  
Author(s):  
ROSANA S.C. ALVES ◽  
FLÁVIO ALÓE ◽  
ADEMIR B. SILVA ◽  
STELLA M. TAVARES

Rhythmic movement disorder, also known as jactatio capitis nocturna, is an infancy and childhood sleep-related disorder charactherized by repetitive movements occurring immediately prior to sleep onset and sustained into light sleep. We report a 19-year-old man with a history of headbanging and repetitive bodyrocking since infancy, occurring on a daily basis at sleep onset. He was born a premature baby but psychomotor milestones were unremarkable. Physical and neurological diagnostic workups were unremarkable. A hospital-based sleep study showed: total sleep time: 178 min; sleep efficiency index 35.8; sleep latency 65 min; REM latency 189 min. There were no respiratory events and head movements occurred at 4/min during wakefulness, stages 1 and 2 NREM sleep. No tonic or phasic electromyographic abnormalities were recorded during REM sleep. A clinical diagnosis of rhythmic movement disorder was performed on the basis of the clinical and sleep studies data. Clonazepam (0.5 mg/day) and midazolam (15 mg/day) yielded no clinical improvement. Imipramine (10 mg/day) produced good clinical outcome. In summary, we report a RMD case with atypical clinical and therapeutical features.

2012 ◽  
Vol 28 (3) ◽  
pp. 371 ◽  
Author(s):  
ArneO Budde ◽  
Sonia Vaida ◽  
Megan Freestone-Bernd

2005 ◽  
Vol 147 (3) ◽  
pp. 393-395 ◽  
Author(s):  
Tamar Etzioni ◽  
Neri Katz ◽  
Eli Hering ◽  
Sarit Ravid ◽  
Giora Pillar

Neurology ◽  
2005 ◽  
Vol 64 (8) ◽  
pp. 1478-1479 ◽  
Author(s):  
P. -Y. Jeannet ◽  
T. Kuntzer ◽  
T. Deonna ◽  
E. Roulet-Perez

1988 ◽  
Vol 33 (2) ◽  
pp. 103-107 ◽  
Author(s):  
Jonathan A.E. Fleming ◽  
Jean Bourgouin ◽  
Peter Hamilton

Six patients between the ages of 25 and 59, with chronic, primary insomnia received the new, non-benzodiazepine, hypnotic zopiclone continuously for 17 weeks after a drug free interval of 12 nights. To qualify for the study, sleep efficiency, determined by a sleep study on two, consecutive, placebo-controlled nights, had to be less than 75%. Patients evaluated their sleep by questionnaire and had sleep studies completed throughout active treatment. Zopiclone (7.5 mg) increased sleep efficiency by decreasing sleep latency, wakefulness after sleep onset and increasing total sleep time. Sleep architecture was minimally affected by zopiclone treatment; no significant changes in delta or REM sleep were observed. The commonest side effect was a bitter or metallic taste. No significant changes in biological functioning were noted throughout the study period. These findings indicate that zopiclone is a safe and effective hypnotic medication which maintains its effectiveness with protracted use.


Author(s):  
V. Mark Durand

Chapter 15 discusses other sleep-related problems, such as sleepwalking, sleeping at the wrong times, excessive sleepiness, and nighttime problems related to anxiety, depression, headaches, rhythmic movement disorder and nighttime teeth grinding (nocturnal bruxism).


2019 ◽  
Vol 15 (01) ◽  
pp. 157-158
Author(s):  
Helen K. Hayward-Koennecke ◽  
Esther Werth ◽  
Philipp O. Valko ◽  
Christian R. Baumann ◽  
Rositsa Poryazova

2012 ◽  
Vol 13 (10) ◽  
pp. 1324-1325 ◽  
Author(s):  
Nicolas Vitello ◽  
Sophie Bayard ◽  
Régis Lopez ◽  
Bertrand Carlander ◽  
Yves Dauvilliers ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document